PHIO PHIO PHARMACEUTICALS CORP revenue, earnings and financials
For the quarter ended June 30, 2026, PHIO PHARMACEUTICALS CORP reported revenue of n/a, net income of −$4.14M and diluted EPS of n/a; for the fiscal year ended December 2025 revenue was n/a.
PHIO annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$9.22M, net income −$8.70M (margin n/a), EPS n/a
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$7.39M, net income −$7.15M (margin n/a), EPS −$9.08
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$10.8M, net income −$10.8M (margin n/a), EPS −$46.76
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$11.5M, net income −$11.5M (margin n/a), EPS −$10.10
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$13.5M, net income −$13.3M (margin n/a), EPS −$12.43
PHIO quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$4.14M, EPS n/a
- Quarter ended Mar 31, 2026: revenue n/a, net income −$4.00M, EPS n/a
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$2.37M, EPS n/a
- Quarter ended Sep 30, 2025: revenue n/a, net income −$2.39M, EPS n/a
- Quarter ended Jun 30, 2025: revenue n/a, net income −$2.17M, EPS −$0.45
- Quarter ended Mar 31, 2025: revenue n/a, net income −$1.77M, EPS −$0.41
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$1.63M, EPS −$3.45
- Quarter ended Sep 30, 2024: revenue n/a, net income −$1.52M, EPS −$1.54
- Quarter ended Jun 30, 2024: revenue n/a, net income −$1.85M, EPS −$3.62
- Quarter ended Mar 31, 2024: revenue n/a, net income −$2.15M, EPS −$0.47
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$1.90M, EPS −$20.09
- Quarter ended Sep 30, 2023: revenue n/a, net income −$2.78M, EPS −$10.25
- Quarter ended Jun 30, 2023: revenue n/a, net income −$2.55M, EPS −$13.27
- Quarter ended Mar 31, 2023: revenue n/a, net income −$3.60M, EPS −$3.15
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$2.73M, EPS −$2.40
- Quarter ended Sep 30, 2022: revenue n/a, net income −$3.58M, EPS −$3.14
- Quarter ended Jun 30, 2022: revenue n/a, net income −$2.53M, EPS −$2.22
- Quarter ended Mar 31, 2022: revenue n/a, net income −$2.64M, EPS −$2.34
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$3.45M, EPS −$11.63
- Quarter ended Sep 30, 2021: revenue n/a, net income −$3.74M, EPS −$0.28
PHIO cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$7.98M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$7.11M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$10.7M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$12.1M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$11.9M, share buybacks n/a
PHIO balance sheet
- Jun 30, 2026: cash $13.0M, total assets $14.3M, total liabilities $1.71M, shareholders' equity $12.6M
- Mar 31, 2026: cash $17.0M, total assets $17.4M, total liabilities $950K, shareholders' equity $16.5M
- Dec 31, 2025: cash $21.0M, total assets $21.5M, total liabilities $1.34M, shareholders' equity $20.1M
- Sep 30, 2025: cash $10.7M, total assets $11.5M, total liabilities $1.67M, shareholders' equity $9.84M
- Jun 30, 2025: cash $10.8M, total assets $11.3M, total liabilities $1.21M, shareholders' equity $10.1M
- Mar 31, 2025: cash $13.3M, total assets $13.4M, total liabilities $1.27M, shareholders' equity $12.2M
- Dec 31, 2024: cash $5.38M, total assets $5.74M, total liabilities $1.02M, shareholders' equity $4.72M
- Sep 30, 2024: cash $5.39M, total assets $5.87M, total liabilities n/a, shareholders' equity $4.95M
Is PHIO profitable?
No. PHIO PHARMACEUTICALS CORP lost $12.9M over the last four quarters.